FARZANA ALAM portrait
  • Research Assistant Professor, Pharmacology And Toxicology

Presentations

  • AAPS Pharm Sci360 (Washington, D.C.); Development of a scientific framework for extension of medication shelf- lives beyond declared expiration dates. Poster, Presented, 11/2018.
  • 15th International Biotechnology Symposium and Exhibition, Abstract number P-S7-0090, Daegu (South Korea); Polyethylene glycol (PEG) conjugated heparin- taurocholate derivative (LHT7) and protamine nanocomplex enhances anti-tumor activity by inhibiting angiogenesis. Poster, Presented, 09/2016.
  • The 15th HU-SNU Joint Symposium, Abstract book 15-16, Seoul (South Korea); Orally active heparin derivative to target TGFβ1 and CXCL12 for the treatment of advanced metastatic breast cancer. Other, Presented, 12/2013.
  • 2013 Asian Federation for Pharmaceutical Sciences, Jeju (South Korea); Functionalized heparin-protamine based self-assembled Nanoparticle for enhance anti-angiogenic effect and tumor distribution. Other, Presented, 10/2013.
  • 5th Asian Arden Conference, Nagoya (Japan); Heparin Based Nano-complex as an Angiogenesis Inhibitor. Poster, Presented, 08/2013.
  • GPEN 2012, Abstract Number O-S-10, Melbourne (Australia); Polyethylene glycol (PEG) conjugated heparin- taurocholate derivative (LHT7) and protamine nanocomplex enhances anti-tumor activity by inhibiting angiogenesis. Other, Presented, 12/2012.

Research Interest

  1. Drug delivery research: Targeted therapy for cancer angiogenesis,  metastasis and chemical-resistant pathways. Focused areas: Ovarian Cancer, Pancreatic Cancer, Oral Cancer and Head and Neck Cancer. 
  1. Educational Research:
    • Active and effecting teaching and learning. 
    • Incorporating generative Ai in the courses to enhance students’ learning

 

Publications

  • Jeong Uk Choi & Ph.D; Xiaojun Zhang; Seung Woo Chung, Ph.D; Mazharul Karim; Farzana Alam, Ph.D; In-San Kim, M.D., Ph.D; Taslim A. Al-Hilal, Ph.D (2022). Targeting angiogenic growth factors using therapeutic glycosaminoglycans on doppel-expressing endothelial cells for blocking angiogenic signaling in cancer. Biomaterials. Published, 03/2022.
  • TA Al-Hilal & A Hossain*, A Alobaida, F Alam, A Keshavarz, N German, E Nozik-Grayck, KR Stenmark, F Ahsan (2021). Design, synthesis and biological evaluations of a long-acting, hypoxia-activated prodrug of fasudil, a ROCK inhibitor, to reduce its systemic side-effects. Journal of Controlled Release. Published, 01/2021.
  • H Kadry & TA Al-Hilal, A Keshavarz, F Alam, C Xu, A Joy, F Ahsan (2018). Multi-purposable filaments of HPMC for 3D printing of Medications with Tailored Drug Release and Timed Absorption. International Journal of Pharmaceutics. Published, 01/2018.
  • F Mahmud & OC Jeon, F Alam, R Maharjan, JU Choi, J Park, S Lee, JW Park, DS Lee, Y Byun (2018). Oral pemetrexed facilitates low-dose metronomic therapy and enhances antitumor efficacy in lung cancer. Journal of Controlled Release. Published, 01/2018.
  • SFL Hanson & MH Terry, DT Moretta, GG Power, SM Wilson, F Alam, F Ahsan, AB Blood, PC Giri (2017). Inhaled Fasudil Lacks Pulmonary Selectivity in Thromboxane-Induced Acute Pulmonary Hypertension in Newborn Lambs. Journal of Cardiovascular Pharmacology and Therapeutics. Published, 01/2017.
  • J Park & SR Hwang, JU Choi, F Alam, Y Byun (2017). Self-assembled nanocomplex of Pegylated protamine and heparin–suramin conjugate for accumulation at the tumor site. International Journal of Pharmaceutics. Published, 01/2017.
  • JU Choi & SW Chung, TA Al-Hilal, F Alam, J Park, F Mahmud, JH Jeong, SY Kim, Y Byun (2017). A heparin conjugate, LHbisD4, inhibits lymphangiogenesis and attenuates lymph node metastasis by blocking VEGF-C signaling pathway. Biomaterials. Published, 01/2017.
  • F Mahmud & SW Chung, F Alam, JU Choi, SW Kim, I-S Kim, SY Kim, DS Lee, Y Byun (2017). Metronomic chemotherapy using orally active carboplatin/deoxycholate complex to maintain drug concentration within a tolerable range for effective cancer management. Journal of Controlled Release. Published, 01/2017.
  • F Alam & TA Al-Hilal, J Park, JW Choi, F Mahmud, SY Kim, DS Lee, Y Byun (2016). Multistage inhibition in breast cancer metastasis by orally active triple conjugate, LHTD4 (low molecular weight heparin-taurocholate-tetrameric deoxycholate). Biomaterials. Published, 01/2016.
  • F Alam & SR Hwang, SW Chung, TA Al-Hilal, J Park, OC Jeon, HT Moon, SY Kim, DS Lee, Y Byun (2016). Molecular weight heparin derivative LHT7 in a Preclinical Model. Drug Development and Industrial Pharmacy. Published, 01/2016.
  • TA Al-Hilal & SW Chung, F Alam, JW Choi, J Park, K Kim, IC Kwon, I-S Kim, SY Kim, Y Byun (2016). Targeting prion-like protien doppel selectively suppresses tumor angiogenesis. The Journal of Clinical Investigation. Published, 01/2016.
  • F Alam & SW Chung, SR Hwang, J Kim, J Park, HT Moon, Y Byun (2015). Preliminary safety evaluation of a taurocholate-conjugated low-molecular-weight heparin derivative (LHT7): a potent angiogenesis inhibitor. Journal of Applied Toxicology. Published, 01/2015.
  • F Alam & TA Al-Hilal, SW Chung, J Park, F Mahmud, DH Seo, HS Kim, DS Lee, Y Byun (2015). Functionalized heparin-protamine based self-assembled nanocomplex for efficient anti-angiogenic therapy. Journal of Controlled Release. Published, 01/2015.
  • J Kim & F Alam, SW Chung, HS Kim, BH Kang, Y Byun (2014). Combinational chemoprevention effect of celecoxib and oral antiangiogenic LHD4 on colorectal carcinogenesis in mice. Anticancer Drugs. Published, 01/2014.
  • TA Al-Hilal & J Park, F Alam, SW Chung, JW Park, K Kim, IC Kwon, IS Kim, SY Kim, Y Byun (2014). Oligomeric bile acid-mediated oral delivery of low molecular weight heparin. Journal of Controlled Release. Published, 01/2014.
  • TA Al-Hilal & SW Chung, F Alam, J Park, KE Lee, H Jeon, K Kim, IC Kwon, IS Kim, SY Kim, Y Byun (2014). Functional transformations of bile acid transporters induced by high-affinity macromolecules. Scientific Reports. Published, 01/2014.
  • F Alam & TA Al-Hilal, SW Chung, DH Seo, F Mahmud, HS Kim, SY Kim, Y Byun (2014). Oral delivery of a potent anti-angiogenic heparin conjugate by chemical conjugation and physical complexation using deoxycholic acid. Biomaterials. Published, 01/2014.
  • TA Al-Hilal & F Alam, JW Park, K Kim, IC Kwon, GH Ryu, Y Byun (2014). Prevention effect of orally active heparin conjugate on cancer-associated thrombosis. Journal of Controlled Release. Published, 01/2014.
  • TA Al-Hilal & F Alam, Y Byun (2013). Oral drug delivery systems using chemical conjugates or physical complexes. Advanced Drug Delivery Reviews. Published, 01/2013.